Talphera Inc
TLPH0.407USD
+0.005+1.19%
交易中 （美东）报价延迟15分钟
6.96M总市值
亏损市盈率 TTM
关于 Talphera Inc 公司
Talphera, Inc.（前身为 AcelRx Pharmaceuticals, Inc.）是一家专业制药公司。该公司专注于开发和商业化用于医疗监督环境的疗法。该公司的萘莫司他候选产品包括 Niyad 和 LTX-608。Niyad 专注于开发用于注射到体外循环中的局部抗凝剂，例如医院急性肾损伤 (AKI) 患者在持续性肾脏替代治疗 (CRRT) 期间的透析循环，以及透析中心接受间歇性血液透析 (IHD) 的慢性肾病患者。LTX-608 是用于直接静脉 (IV) 输注的萘莫司他制剂，应被研究和开发为治疗 COVID、急性呼吸窘迫综合征 (ARDS) 弥漫性血管内凝血 (DIC) 和急性胰腺炎的潜在抗病毒药物。该公司还致力于开发两种预充式注射器，即 Fedsyra 和 PFS-02。
公司简介
公司代码TLPH
公司名称Talphera Inc
上市日期Feb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
员工数量13
证券类型Ordinary Share
年结日Feb 11
公司地址1850 Gateway Drive
城市SAN MATEO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94404
电话16502163500
网址https://talphera.com/
公司代码TLPH
上市日期Feb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Independent Director
Independent Director
--
--
Mr. Vincent J. (Vince) Angotti
Mr. Vincent J. (Vince) Angotti
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Director
Independent Director
--
--
Dr. Stephen J. Hoffman, M.D., Ph.D.
Dr. Stephen J. Hoffman, M.D., Ph.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
单位: USD更新时间: 3月5日 周三
单位: USD更新时间: 3月5日 周三
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
股东统计
更新时间: 8月1日 周五
更新时间: 8月1日 周五
持股股东
股东类型
持股股东
持股股东
占比
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
持股股东
持股股东
占比
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
股东类型
持股股东
占比
Hedge Fund
25.46%
Investment Advisor
4.28%
Individual Investor
2.62%
Investment Advisor/Hedge Fund
1.06%
Research Firm
0.45%
Venture Capital
0.07%
Other
66.06%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
79
6.96M
33.93%
-504.17K
2025Q1
82
6.66M
34.60%
-832.94K
2024Q4
84
5.24M
30.79%
-2.31M
2024Q3
100
5.33M
31.39%
-2.35M
2024Q2
109
5.51M
32.40%
-2.29M
2024Q1
113
5.56M
32.76%
-881.00K
2023Q4
117
5.91M
35.12%
-445.19K
2023Q3
127
7.03M
43.10%
+3.84M
2023Q2
136
1.17M
10.69%
-920.00K
2023Q1
169
1.22M
11.24%
-974.29K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Rosalind Advisors, Inc.
2.00M
9.77%
+1.39M
+226.41%
Mar 31, 2025
Nantahala Capital Management, LLC
1.99M
9.72%
--
--
Apr 25, 2025
Armistice Capital LLC
890.35K
4.34%
-661.26K
-42.62%
Dec 31, 2023
Bleichroeder LP
426.62K
2.08%
+426.62K
--
Mar 31, 2025
Angotti Vincent J
367.85K
1.79%
+265.56K
+259.62%
Apr 25, 2025
Rock Springs Capital Management LP
316.46K
1.54%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
237.53K
1.16%
-3.44K
-1.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
165.61K
0.81%
+2.40K
+1.47%
Mar 31, 2025
Values First Advisors, Inc.
97.32K
0.47%
+771.00
+0.80%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
91.55K
0.45%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
公告日期
类型
比率
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
